Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ASTRAZENECA PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ASTRAZENECA PHARMA Mar-23 |
ADCOCK INGRAM Jun-14 |
ASTRAZENECA PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,620 | 316 | - | |
Low | Rs | 2,438 | 228 | - | |
Sales per share (Unadj.) | Rs | 401.2 | 94.0 | - | |
Earnings per share (Unadj.) | Rs | 39.7 | -23.7 | - | |
Cash flow per share (Unadj.) | Rs | 46.2 | -19.6 | - | |
Dividends per share (Unadj.) | Rs | 16.00 | 0 | - | |
Avg Dividend yield | % | 0.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 234.4 | 73.8 | - | |
Shares outstanding (eoy) | m | 25.00 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 7.5 | 2.9 | 260.9% | |
Avg P/E ratio | x | 76.3 | -11.5 | -664.1% | |
P/CF ratio (eoy) | x | 65.5 | -13.9 | -472.9% | |
Price / Book Value ratio | x | 12.9 | 3.7 | 350.4% | |
Dividend payout | % | 40.3 | 0 | - | |
Avg Mkt Cap | Rs m | 75,718 | 45,919 | 164.9% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 2,591 | 2,882 | 89.9% | |
Avg. sales/employee | Rs Th | 0 | 3,696.8 | - | |
Avg. wages/employee | Rs Th | 0 | 671.3 | - | |
Avg. net profit/employee | Rs Th | 0 | -931.5 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 10,030 | 15,870 | 63.2% | |
Other income | Rs m | 261 | 111 | 234.8% | |
Total revenues | Rs m | 10,291 | 15,982 | 64.4% | |
Gross profit | Rs m | 1,249 | -2,750 | -45.4% | |
Depreciation | Rs m | 163 | 685 | 23.7% | |
Interest | Rs m | 6 | 430 | 1.5% | |
Profit before tax | Rs m | 1,341 | -3,754 | -35.7% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 348 | 235 | 148.4% | |
Profit after tax | Rs m | 993 | -3,999 | -24.8% | |
Gross profit margin | % | 12.5 | -17.3 | -71.9% | |
Effective tax rate | % | 26.0 | -6.2 | -415.4% | |
Net profit margin | % | 9.9 | -25.2 | -39.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 9,359 | 11,624 | 80.5% | |
Current liabilities | Rs m | 4,844 | 6,540 | 74.1% | |
Net working cap to sales | % | 45.0 | 32.0 | 140.5% | |
Current ratio | x | 1.9 | 1.8 | 108.7% | |
Inventory Days | Days | 49 | 111 | 44.6% | |
Debtors Days | Days | 39 | 124 | 31.6% | |
Net fixed assets | Rs m | 2,061 | 6,775 | 30.4% | |
Share capital | Rs m | 50 | 74 | 67.9% | |
Net worth | Rs m | 5,861 | 12,457 | 47.1% | |
Long term debt | Rs m | 0 | 4,377 | 0.0% | |
Total assets | Rs m | 11,421 | 23,531 | 48.5% | |
Interest coverage | x | 213.9 | -7.7 | -2,765.8% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0.9 | 0.7 | 130.2% | |
Return on assets | % | 8.7 | -15.2 | -57.7% | |
Return on equity | % | 16.9 | -32.1 | -52.8% | |
Return on capital | % | 23.0 | -19.8 | -116.0% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 583 | 1,355 | 43.0% | |
From Investments | Rs m | 181 | -416 | -43.5% | |
From Financial Activity | Rs m | -245 | 3,973 | -6.2% | |
Net Cashflow | Rs m | 519 | 4,912 | 10.6% |
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ASTRAZENECA PHARMA With: LACTOSE INDIA FDC BH.IMMUN&BIO ISHITA DRUGS OMKAR PHARMACHEM
Indian share markets continued the momentum as the session progressed and ended the higher.